News Release
Asian Clinical Trials (ACT), the CRO division of Suven Commences clinical research services from Raleigh, North Carolina, USA
HYDERABAD, INDIA (August 12, 2008) – Asian Clinical Trials (ACT), the CRO division of Suven Life Sciences has announced the addition of a new regional office at Raleigh, North Carolina, USA headed by Dr. Hameed Allaudeen, Vice President of Clinical Research & Regulatory Affairs and supported by Ms. Deborah Levitt Smith, Executive Director of Business Development. This is in addition to existing operations from Monmouth Junction, New Jersey.
Dr. Allaudeen has over 20 years of drug discovery and development experience in both academia and industry. Prior to joining ACT, Dr. Allaudeen worked at Pfizer Global Research and Development conducting clinical studies with both early development and full development drug candidates. At Pfizer he has conducted studies in multiple therapeutic areas including oncology, infectious diseases and respiratory diseases. Earlier Dr. Allaudeen also had his stint in GlaxoSmithKline, US FDA and small biotech companies. He had a productive research career at Yale University. He published 43 full papers in peer-reviewed, international journals, and 65 abstracts. His focus has always been on operational excellence.
Ms. Smith has over 15 years of professional experience within the pharmaceutical-related industry. Before joining ACT, Ms. Smith was the Executive Director of Business Development for Rho, Inc., a CRO based in Chapel Hill, NC. Prior to Rho, she had worked in various capacities in Marketing and Business Development in Caramedica Pharmaceuticals Inc., PPD, Inc. and for Biovail Pharmaceuticals, Inc. Ms. Smith brings a diverse knowledge base to ACT that offers a perspective from both the sponsor and the vendor side of the business.
Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade. Asian Clinical Trials (ACT) is Clinical Research Operations division of Suven, providing complete solutions for global pharmaceutical, biotechnology and medical device companies in clinical research. ACT data management solutions are supported by fully validated technology platform like Oracle Clinical 4.5.
Suven has R&D strength of more than 300 professionals with the state of the art infrastructure for Drug Discovery and development and Clinical Research activities and the front end project management services from New Jersey and clinical research services from North Carolina, USA. For more information on Suven/ACT, please visit our Web site at http://www.suven.com & www.act-india.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;